Cyclohexane derivative, prodrug thereof and salt thereof,...

Details Cyclohexane derivative, prodrug thereof and salt thereof,... Cyclohexane derivative, prodrug thereof and salt thereof,...

2005-07-26

2011-11-01

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S738000, C546S301000, C548S376100, C548S490000, C549S058000, C549S066000, C549S445000, C549S469000, C562S405000

Reexamination Certificate

active

08048897

ABSTRACT:
A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I):(wherein A is —O—, —CH2—, or —NH—; n is an integer selected between 0 and 1; R6and R7each independently is hydrogen or C1-6alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1to Q5;Ar1is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

REFERENCES:
patent: 5962686 (1999-10-01), Ichihara et al.
patent: 6048842 (2000-04-01), Tsujihara et al.
patent: 2001/0041674 (2001-11-01), Tomiyama et al.
patent: 2002/0137903 (2002-09-01), Ellsworth et al.
patent: 2003/0114390 (2003-06-01), Washburn et al.
patent: 2004/0110693 (2004-06-01), Trepel et al.
patent: 2493391 (2004-01-01), None
patent: 2508024 (2004-06-01), None
patent: 2508226 (2004-06-01), None
patent: 0598359 (1994-05-01), None
patent: 0684254 (1995-11-01), None
patent: 1213296 (2002-06-01), None
patent: 1270584 (2003-01-01), None
patent: 1329456 (2003-07-01), None
patent: 1338603 (2003-08-01), None
patent: 1344780 (2003-09-01), None
patent: 1354888 (2003-10-01), None
patent: 1364957 (2003-11-01), None
patent: 1364958 (2003-11-01), None
patent: 1367060 (2003-12-01), None
patent: 1389621 (2004-02-01), None
patent: 1400529 (2004-03-01), None
patent: 1405859 (2004-04-01), None
patent: 1500403 (2005-01-01), None
patent: 1528066 (2005-05-01), None
patent: 1553094 (2005-07-01), None
patent: 1577317 (2005-09-01), None
patent: 827006 (1996-01-01), None
patent: 9124684 (1997-05-01), None
patent: 9124685 (1997-05-01), None
patent: 9188625 (1997-07-01), None
patent: 2000-80041 (2000-03-01), None
patent: 200080041 (2000-03-01), None
patent: 2001288178 (2001-10-01), None
patent: 200312686 (2003-01-01), None
patent: 0127128 (2001-04-01), None
patent: WO 01/27128 (2001-04-01), None
patent: 0158899 (2001-08-01), None
patent: WO 01/68660 (2001-09-01), None
patent: 0174834 (2001-10-01), None
patent: 0174835 (2001-10-01), None
patent: WO 02/064606 (2002-08-01), None
patent: 02083066 (2002-10-01), None
patent: WO 02/083066 (2002-10-01), None
patent: 03011880 (2003-02-01), None
patent: 03020737 (2003-03-01), None
patent: 03099836 (2003-12-01), None
patent: 2004007517 (2004-01-01), None
patent: WO 2004/007517 (2004-01-01), None
patent: WO 2004/013118 (2004-02-01), None
patent: WO 2004/014931 (2004-02-01), None
patent: 2004052902 (2004-06-01), None
patent: 2004052903 (2004-06-01), None
patent: WO2005051938 (2005-06-01), None
Adachi et al., Metabolism, “T-1095, a Renal Na+-Glucose Transporter Inhibitor, Improves Hyperglycemia in Streptozotocin-Induced Diabetic Rats”, vol. 49, issue 8, pp. 990-995 (2000).
MayoClinic.com “Type 1 diabetes”; aso available at http://www.mayoclinic.com/health/type-1-diabetes; last viewed Feb. 1, 2010.
Testa, Bernard, Biochemical Pharmacology, “Prodrug research: futile or fertile?”, vol. 68, pp. 2097-2106 (2004).
Ettmayer, Peter, Journal of Medicinal Chemistry, “Lessons Learned from Marketed and Investigational Prodrugs”, vol. 47, issue 10, pp. 2393-2404 (2004).
WordNet Search 3.0 “prevent”; also available at http://wordnetweb.princeton.edu/perl/webwn; last viewed Nov. 14, 2007.
Kenji Tsujihara et al., “Na+-Glucose Cotrans[orter Inhibitors as Antidiabetics. I. Synthesis and pharmacological Properties of 4′-Dehydroxyphlorizin Derivatives Based on a New Concept”, Chem. Pharm. Bull., vol. 44, No. 6, 1996 Pharmaceutical Societyof Japan, pp. 1174-1180.
Mitsuya Honou et al., “Na+-Glucose Cotransporter Inhibitors as Autidiabetic Agents. III. Synthesis and Pharmacological Properties of 4′-Dehydroxyphlorizin Derivatives Modified at the OH Groups of the Glucose Moiety”, Chem\Pharm vol. 46, No. 10, Oct. 1998, pp. 1545-1555.
Mitsuya Honou et al., “Na+-Glucose Cotransporter Inhibitors as Antidiabetic Agents. II. Synthesis ans Structure-Activity Relationships of 4′-Dehydroxyphlorizin Derivatives”, Chem Pharm Bull., vol. 46, No. 1, 1998, p. 22-33.
Kenji Tsujihara et al., Na+-Glucose Cotransporter (SGLT) Inhibitors as Antidiabetic Agents. 4. Synthesis and Pharmacological Properties of 4′-Dehydroxyphlorizin Derivatives Substituted on the B Ring, J. Med. Chem. vol. 42, No. 26, Dec. 1999, pp. 5311-5324.
J.T.Link et al., “A method for preparing C-glycosides related to phlorizin”, Tetrahedron Letters vol. 41, 2000, pp. 9213-9217.
Koji Obsumi et al., “Pyrazole-O-Glucosides as Novel Na+-Glucose Cotransporter (SGLT) Inhibitors”, Bioorganic & Medicinal Chemistry Letters, vol. 13, 2003, pp. 2269-2272.

Affiliated with

Also associated with

Rating

Cyclohexane derivative, prodrug thereof and salt thereof,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclohexane derivative, prodrug thereof and salt thereof,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclohexane derivative, prodrug thereof and salt thereof,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4286835